LDLR and atherosclerosis: PRMT5 inhibition by low‐dose GSK3326595 treatment does not affect the inflammatory state or atherosclerosis susceptibility of Western‐type diet‐fed LDL receptor knockout mice, while it induces hepatic triglyceride accumulation.